Effect of Septimeb™ as a new natural extract on severe sepsis: A randomized clinical trial

Background: septimeb as a herbal medicine has regulatory effects on inflammation. this study set to evaluate the effects of septimeb among patients with sepsis on inflammatory biomarkers and survival rate. methods: in this randomized clinical trial,51 patients with sepsis from the icu and medical ward of imam khomeini hospital were divided into two groups: septimeb (n=25) and control group (n=26). in the control group,the patients received a standard treatment only for 7 days,while septimeb group received septimeb (6cc vial with 500cc serum glucose infusion 5% daily for one to two hours) plus standard treatment of sepsis for 7 days. then,blood samples were analyzed. apache (acute physiologic and chronic health evaluation),sofa (sequential organ failure assessment),and gcs (glasgow coma score) values were calculated daily. results: treatment with septimeb showed a significant decrease in sofa value (1.54±0.83) compared to the control group (2.39±0.88) (p < 0.001) and a significant increase in gcs value (14.46±0.88) compared to the control group (12.86±1.78) (p < 0.001). improvements of these values can confirm the potential of septimeb in the reduction of severity of sepsis (p < 0.05). there were significant decreases in lactate and blood sugar and wbc levels. in addition,inflammatory factors such as esr (septimeb group: 52.07±34.80,control group: 51.75±42.10,p=0.98) and crp (septimeb group: 48.86±23.21,control group: 49.93±36.22,p=0.92) decreased,but did not show a significant reduction. conclusion: septimeb has positive effects on reduction of the severity of sepsis which leads to reduction of patients' mortality rates.